# A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

> **NCT06476808** · PHASE1 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 240 (estimated)

## Conditions studied

- High-grade Serous Ovarian Carcinoma (HGSOC)
- Uterine Serous Carcinoma (USC)
- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** BMS-986463

## Key facts

- **NCT ID:** NCT06476808
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-06
- **Primary completion:** 2028-12-19
- **Final completion:** 2028-12-19
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06476808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06476808, "A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06476808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*